OPR2 Antibody

What is ORM2 and why is it important in research?

ORM2 (orosomucoid 2, also known as AGP2 or OMD 2) belongs to the calycin superfamily and Lipocalin family. It functions primarily as a transport protein in the bloodstream, binding various hydrophobic ligands within its beta-barrel domain. ORM2 is particularly important in research involving acute phase protein responses, drug transport mechanisms, and immunomodulatory functions . Researchers target this protein to understand its role in various physiological and pathological conditions, particularly in inflammatory responses and drug pharmacokinetics.

What are the key applications for ORM2 antibodies in laboratory research?

ORM2 antibodies are versatile tools employed across multiple experimental techniques. According to validation data, these antibodies can be effectively utilized in Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC), Immunofluorescence (IF/ICC), Chromatin Immunoprecipitation (ChIP), and ELISA applications . Each application offers distinct advantages for investigating ORM2 expression, localization, and interactions in various cellular and tissue contexts. The choice of application depends on the specific research question, with WB primarily used for expression quantification, IHC/IF for localization studies, IP for protein interaction analyses, and ChIP for DNA-protein binding investigations.

What is the molecular weight range expected when detecting ORM2 in experiments?

When detecting ORM2 protein using antibody-based methods, researchers should anticipate observed molecular weights in two distinct ranges: 24-28 kDa and 41-47 kDa . While the calculated molecular weight based on amino acid sequence is approximately 24 kDa, the higher molecular weight band (41-47 kDa) likely represents post-translationally modified forms of the protein, particularly glycosylated variants. This discrepancy between calculated and observed molecular weights is critical for accurate experimental interpretation and troubleshooting.

What are the optimal antibody dilutions for different ORM2 detection methods?

Optimal antibody dilutions vary significantly based on the experimental technique:

These ranges serve as starting points, and researchers should conduct optimization experiments with their specific samples to determine ideal conditions . Factors influencing optimal dilution include sample type, expression level, and detection method sensitivity.

What sample types and cell lines have been validated for ORM2 antibody studies?

Current validation data confirms reactivity with human samples across various experimental applications. Specifically, Western blot positivity has been demonstrated in L02 and A549 cell lines, while immunoprecipitation has been validated in L02 cells . For immunohistochemistry, human liver tissue shows consistent positive staining, and HEK-293 cells have been successfully used for immunofluorescence studies. When exploring new sample types, researchers should include appropriate positive controls from these validated sources.

What are the recommended antigen retrieval methods for ORM2 immunohistochemistry?

For optimal immunohistochemical detection of ORM2, two antigen retrieval methods have been validated:

• Primary recommendation: TE buffer at pH 9.0

• Alternative approach: Citrate buffer at pH 6.0

The choice between these methods depends on tissue type, fixation conditions, and staining automation systems . Extended fixation times may require more aggressive retrieval conditions (higher pH or longer incubation times). A comparative optimization experiment testing both conditions is advisable when establishing a new IHC protocol.

How can ORM2 antibodies be used to investigate drug transport mechanisms?

ORM2 protein functions as a transport protein binding various hydrophobic ligands in its beta-barrel domain . For investigating drug transport mechanisms, researchers can employ a combination of techniques:

• Co-immunoprecipitation using anti-ORM2 antibodies to pull down protein-drug complexes

• Competitive binding assays comparing displacement of known ligands by experimental drugs

• ChIP-seq approaches to identify genome-wide binding patterns related to drug response elements

These approaches can reveal how pharmaceuticals interact with ORM2, potentially affecting their bioavailability and therapeutic efficacy. When designing such experiments, it's crucial to include appropriate negative controls and concentration gradients to establish binding specificity.

What approaches can address discrepancies between expected and observed molecular weights in ORM2 detection?

The observation of ORM2 at both 24-28 kDa and 41-47 kDa presents an analytical challenge requiring methodical investigation:

• Deglycosylation experiments: Treat samples with enzymes like PNGase F before Western blotting to remove N-linked glycans

• Phosphatase treatment: Apply lambda phosphatase to determine if phosphorylation contributes to the higher molecular weight band

• Sample preparation variations: Compare reducing vs. non-reducing conditions to assess disulfide bond contributions

• Mass spectrometry analysis: Characterize the exact modifications present on the different ORM2 forms

These approaches can help distinguish between post-translational modifications, alternative splice variants, and potential protein complexes resistant to denaturation.

How can researchers effectively study ORM2 in the context of acute phase responses?

As ORM2 functions in acute phase responses, researchers can design comprehensive experimental approaches:

• Time-course experiments following inflammatory stimulation (e.g., LPS, cytokines) to track ORM2 expression changes

• Comparison of ORM2 expression across different inflammatory models (sterile vs. infectious inflammation)

• Correlation studies between ORM2 levels and other acute phase proteins

• Cell-specific knockout models to determine tissue-specific contributions to circulating ORM2 levels

These approaches should incorporate both in vitro cell culture systems and in vivo models to capture the complex regulation of acute phase proteins. Measuring both mRNA and protein levels can help distinguish between transcriptional and post-transcriptional regulatory mechanisms.

How do polyclonal and monoclonal ORM2 antibodies compare in research applications?

The choice between polyclonal and monoclonal antibodies presents important trade-offs:

• Polyclonal antibodies (like 11199-1-AP ):

  • Advantage: Recognize multiple epitopes, potentially increasing sensitivity

  • Advantage: More tolerant of minor protein denaturation or modifications

  • Limitation: Batch-to-batch variation can affect reproducibility

  • Optimal for: Initial exploratory studies and applications requiring high sensitivity

• Monoclonal antibodies:

  • Advantage: Consistent specificity with minimal batch variation

  • Advantage: Reduced background in complex samples

  • Limitation: May lose reactivity if the single epitope is modified or masked

  • Optimal for: Quantitative studies requiring high reproducibility

What are common technical challenges when using ORM2 antibodies and how can they be addressed?

Researchers frequently encounter several technical challenges when working with ORM2 antibodies:

• Multiple band detection: Address by using positive controls, knockout validation, peptide competition assays, and subcellular fractionation

• Background in immunostaining: Improve with careful titration, extended blocking steps, and alternative detection systems

• Weak signal in liver tissue: Enhance by optimizing antigen retrieval with TE buffer at pH 9.0 as recommended

• Non-specific precipitation in IP experiments: Resolve with pre-clearing steps and more stringent wash conditions

Systematic troubleshooting should modify one variable at a time while maintaining appropriate controls to isolate the problematic step in the protocol.

How does ORM2 antibody performance compare with ORM1 antibody in dual-detection experiments?

When simultaneously investigating ORM1 and ORM2:

• Cross-reactivity assessment: The product information indicates 11199-1-AP targets ORM1/2 , suggesting potential cross-reactivity between these closely related proteins

• Differential expression analysis: Using both antibodies in parallel can help identify tissue-specific expression patterns

• Sequential immunoprecipitation: Can be employed to distinguish unique protein interaction partners

• Isoform-specific silencing: Combined with antibody detection can definitively attribute signals to specific isoforms

When designing experiments targeting both proteins, researchers should carefully validate antibody specificity using recombinant proteins or knockout/knockdown controls.

How might antibody engineering approaches improve ORM2 antibody specificity and utility?

Recent advances in antibody engineering present opportunities for enhanced ORM2 research tools:

• De novo antibody design using generative artificial intelligence could significantly improve specificity by optimizing binding domains

• Fragment-based approaches can generate smaller antibody derivatives with improved tissue penetration for in vivo imaging

• Site-specific modifications at complementarity-determining regions (CDRs) can enhance epitope recognition

• Bispecific antibody formats combining ORM2 recognition with other targets could enable novel functional studies

These engineering approaches can overcome current limitations in cross-reactivity and enable new experimental paradigms for studying ORM2 biology.

What insights from immunological studies of bacterial antigens might apply to ORM2 antibody development?

Studies on antibody responses to bacterial antigens like Klebsiella pneumoniae O-antigens offer valuable perspectives for ORM2 antibody development:

• The observation that immune evasion drives prevalence of certain bacterial serotypes parallels challenges in generating antibodies against poorly immunogenic proteins

• The synergistic protection seen when antibodies complement antibiotic therapy suggests potential for combination approaches using ORM2 antibodies with other therapeutics

• Techniques used to identify protective monoclonal antibodies against bacterial targets could be adapted for ORM2

• Understanding the relationship between antigen structure complexity and immunogenicity may inform better immunogen design for ORM2 antibody generation

These cross-disciplinary insights may help overcome challenges in generating high-quality antibodies against relatively conserved proteins like ORM2.

How can researchers evaluate potential cross-reactivity between ORM2 antibodies and other members of the Lipocalin family?

Given ORM2's membership in the Lipocalin family, cross-reactivity assessment is crucial:

• Sequence alignment analysis to identify regions of homology with other family members

• Competitive ELISA assays using recombinant Lipocalin proteins to quantify relative binding affinities

• Immunoabsorption studies with related proteins to deplete cross-reactive antibodies

• Knockout/knockdown validation in cell models expressing multiple Lipocalin family members

These methods help establish specificity profiles important for interpreting experimental results, particularly in contexts where multiple Lipocalin proteins may be present.

What are the optimal storage and handling conditions for maintaining ORM2 antibody performance?

To preserve antibody functionality:

• Storage temperature: Maintain at -20°C for long-term stability

• Aliquoting: Generally unnecessary for -20°C storage of the 11199-1-AP preparation

• Freeze-thaw cycles: Minimize to prevent degradation

• Working solution preparation: Dilute in appropriate buffers immediately before use

• Stability timeframe: Product is stable for one year after shipment when properly stored

Researchers should carefully monitor lot-to-lot variation and include internal standards when comparing experiments performed with different antibody preparations.

How should researchers approach validation of ORM2 antibody specificity in new experimental systems?

A comprehensive validation strategy includes:

• Positive controls: Utilize cell lines with confirmed reactivity (L02, A549, HEK-293)

• Negative controls: Include samples with ORM2 knockdown/knockout or tissues known not to express the protein

• Peptide competition: Pre-incubate antibody with immunizing peptide to confirm binding specificity

• Orthogonal detection methods: Compare results using alternative antibodies or detection approaches

• Recombinant protein standards: Include concentration gradients of purified ORM2 to establish detection limits